Feb. 9 at 4:50 PM
$SKYE Well SKYE is kind of entering dangerous territory share pricewise. Nothing good happens down here. 1st, delisting warnings from the NASDAQ probably have already been issued to SKYE, so the risk of a reverse split is high. 2nd, SKYE will need cash badly in order to run 2B trials for the Combo therapy and the large dose mono therapy, well diluting from here will not net them enough money to run both of those trials to completion. If they dilute 20M shares at .70 a share they are only raising
$14M, which will not be enough to do anything and a dilution that size would send shares into penny status. 3rd, even if they try to dilute, not sure there will be many investors who will buy the diluted shares. So dilution is probably no long an option. Lastly, any more bad news(Hence why they postponed the 300mg dose results from the 1st qtr to the 3rd) will send this dangerously low. Right now most institutional investors would take a
$5 buyout. Not much leverage when the SP is this low.
